Coloplast A/s Class B · OMXCOP:COLO_B
Coloplast A/s Class B — H1 2019/20 Earnings Presentation
9 slides from Coloplast A/s Class B's earnings presentation, May 6, 2020
Slide 1: Making life easier_ Coloplast Earnings Conference Call H1 2019/20
Making life easier_ Coloplast Earnings Conference Call H1 2019/20 6 May 2020 Making life easier Ostomy Care, Continence Care, Wound & Skin Care and Interventional Urology
Slide 2: Forward-looking statements
Forward-looking statements The forward-looking statements contained in this presentation, including forecasts of sales and earnings performance, are not guarantees of future results and are subject to risks, uncertainties and assumptions that are difficult to predict. The forward-looking statements
Slide 3: An update on how Coloplast is navigating the COVID-19 pandemic
An update on how Coloplast is navigating the COVID-19 pandemic • Three key priorities: keeping our people safe, continuing to serve our customers and maintaining business operations • Global guidelines, safety measures and contingency plans implemented • Support consumers with dependable delivery of
Slide 4: Continued solid performance in Q2 impacted by COVID-19 outbreak and stock building in primarily Europe
Continued solid performance in Q2 impacted by COVID-19 outbreak and stock building in primarily Europe Q2 Highlights Revenue growth +9% • Organic growth of 9% and 10% reported growth in DKK Reported revenue (DKKm) +8% • Chronic Care delivered a strong underlying growth in Q2 ex-China Organic growth
Slide 5: Solid growth in Chronic Care in Q2 lifted by stock building in Europe; China & Interventional Urology negatively impacted
Solid growth in Chronic Care in Q2 lifted by stock building in Europe; China & Interventional Urology negatively impacted Q2 19/20 revenue by business area Q2 19/20 revenue by geography Business Reported revenue Organic growth Share of organic Geographic Reported revenue Organic growth Share of orga
Slide 6: H1 2019/20 reported revenue grew 9% driven by solid organic growth of 8%
H1 2019/20 reported revenue grew 9% driven by solid organic growth of 8% Comments Revenue development • H1 2019/20 reported revenue increased by DKK 813m (DKKm) or 9% compared to H1 2018/19 83 9,535 • The majority of growth was driven by organic growth 730 contributing DKK 730m or 8% to reported rev
Slide 7: EBIT grew 14% in H1 2019/20
EBIT grew 14% in H1 2019/20 Comments EBIT margin development (%) • Gross margin of 68% in DKK compared to 67% last year 0.4 -0.3 • Positive impact from operating leverage driven by revenue growth, GOP4 and the closure of the Thisted factory in June 2019 31.6 0.4 31.3 • Negative impact from product m
Slide 8: Financial guidance for FY 2019/20 – updated capex guidance
Financial guidance for FY 2019/20 – updated capex guidance Guidance 2019/20 Guidance 2019/20 (DKK)* Key assumptions • The situation in Interventional Urology gradually normalises during H2 • The situation in China in Ostomy Care and Wound Care gradually normalises during H2 Sales growth 4-6% • The l
Slide 9: Our mission, values and vision
Our mission Making life easier for peoplé with intimate healthcare needs Our values Closeness... to better understand. - Passion... to make a difference Respect and responsibility... to 0 guide | US: Our vision Setting the global standard for listening and responding: Coloplast Group - Ostomy Care /